학술논문

Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort
Document Type
article
Source
JHEP Reports, Vol 5, Iss 6, Pp 100719- (2023)
Subject
Immune checkpoint inhibitors
Immune-related adverse events
Drug-induced liver injury
Cancer
Hepatitis
Cholangitis
Diseases of the digestive system. Gastroenterology
RC799-869
Language
English
ISSN
2589-5559
Abstract
Background & Aims: Immune checkpoint inhibitors (ICIs) have changed the landscape of cancer therapy. Liver toxicity occurs in up to 25% of patients treated with ICIs. The aim of our study was to describe the different clinical patterns of ICI-induced hepatitis and to assess their outcome. Methods: We conducted a retrospective observational study of patients with checkpoint inhibitor-induced liver injury (CHILI) discussed in multidisciplinary meetings between December 2018 and March 2022 in three French centres specialised in ICI toxicity management (Montpellier, Toulouse, Lyon). The hepatitis clinical pattern was analysed by the ratio of serum alanine aminotransferase (ALT) and alkaline phosphatase (ALP) (R value = (ALT/ULN)/(ALP/ULN)) for characterisation as cholestatic (R ≤2), hepatocellular (R ≥5), or mixed (2